BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29509268)

  • 1. Atorvastatin improves plaque stability in diabetic atherosclerosis through the RAGE pathway.
    Zhou F; Tan Y; Chen XH; Wu FL; Yang DJ; Zhang XW; Wu XM; Deng YQ
    Eur Rev Med Pharmacol Sci; 2018 Feb; 22(4):1142-1149. PubMed ID: 29509268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin Blocks Advanced Glycation End Products Induced Reduction in Macrophage Cholesterol Efflux Mediated With ATP-Binding Cassette Transporters G 1.
    Xu L; Wang YR; Li PC; Feng B
    Circ J; 2019 Aug; 83(9):1954-1964. PubMed ID: 31378770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
    Guo X; Wang L; Xia X; Wang P; Li X
    Biomed Pharmacother; 2019 Jan; 109():1445-1453. PubMed ID: 30551396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.
    Gao H; Li H; Li W; Shen X; Di B
    Med Sci Monit; 2017 Dec; 23():6121-6131. PubMed ID: 29278639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
    Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of atorvastatin on AGEs-induced injury of cerebral cortex via inhibiting NADPH oxidase -NF-κB pathway in ApoE
    Li Z; Yang P; Feng B
    Mol Biol Rep; 2020 Dec; 47(12):9479-9488. PubMed ID: 33210255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis.
    Liu M; Yu Y; Jiang H; Zhang L; Zhang PP; Yu P; Jia JG; Chen RZ; Zou YZ; Ge JB
    Acta Pharmacol Sin; 2013 Jun; 34(6):830-6. PubMed ID: 23564080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antioxidant N-acetylcysteine promotes atherosclerotic plaque stabilization through suppression of RAGE, MMPs and NF-κB in ApoE-deficient mice.
    Lu Y; Qin W; Shen T; Dou L; Man Y; Wang S; Xiao C; Li J
    J Atheroscler Thromb; 2011; 18(11):998-1008. PubMed ID: 21873804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
    Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.
    Lu L; Peng WH; Wang W; Wang LJ; Chen QJ; Shen WF
    J Zhejiang Univ Sci B; 2011 Aug; 12(8):652-9. PubMed ID: 21796806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.
    Soro-Paavonen A; Watson AM; Li J; Paavonen K; Koitka A; Calkin AC; Barit D; Coughlan MT; Drew BG; Lancaster GI; Thomas M; Forbes JM; Nawroth PP; Bierhaus A; Cooper ME; Jandeleit-Dahm KA
    Diabetes; 2008 Sep; 57(9):2461-9. PubMed ID: 18511846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.
    Li P; Tang Z; Wang L; Feng B
    Mol Med Rep; 2017 Sep; 16(3):3421-3426. PubMed ID: 28713911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis.
    Belmokhtar K; Robert T; Ortillon J; Braconnier A; Vuiblet V; Boulagnon-Rombi C; Diebold MD; Pietrement C; Schmidt AM; Rieu P; Touré F
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):800-9. PubMed ID: 26988587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
    Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
    J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice].
    Fernández-Laso V; Sastre C; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Clin Investig Arterioscler; 2015; 27(1):17-25. PubMed ID: 25027757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integral role of receptor for advanced glycation end products (RAGE) in nondiabetic atherosclerosis.
    Uekita H; Ishibashi T; Shiomi M; Koyama H; Ohtsuka S; Yamamoto H; Yamagishi S; Inoue H; Itabe H; Sugimoto K; Kamioka M; Ohkawara H; Wada I; Yasuchika T
    Fukushima J Med Sci; 2019; 65(3):109-121. PubMed ID: 31915324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Anti-Atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin-An Experimental Study.
    Stasinopoulou M; Kostomitsopoulos N; Kadoglou NPE
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMTP-44D Inhibits Atherosclerotic Plaque Formation in Apolipoprotein-E Null Mice Partly by Suppressing the AGEs-RAGE Axis.
    Terasaki M; Shibata K; Mori Y; Saito T; Matsui T; Ohara M; Fukui T; Hasumi K; Higashimoto Y; Nobe K; Yamagishi SI
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice.
    Watson AM; Li J; Samijono D; Bierhaus A; Thomas MC; Jandeleit-Dahm KA; Cooper ME
    Atherosclerosis; 2014 Aug; 235(2):444-8. PubMed ID: 24945577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of soluble RAGE in disturbed flow-induced atherogenesis.
    Ha CH; Kim S; Chung J; An SH; Park S; Choi D; Kwon K
    Int J Mol Med; 2013 Aug; 32(2):373-80. PubMed ID: 23708564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.